Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336109 | 1.00 | HDAC6 (0.58) | HDAC6HDAC1 | |
| SCHEMBL26530410 | 0.91 | HDAC6 (0.48) | HDAC6HDAC1 | |
| SCHEMBL26530034 | 0.87 | HDAC6 (0.52) | HDAC6HDAC1 | |
| SCHEMBL26529949 | 0.87 | HDAC6 (0.55) | HDAC6HDAC1 | |
| SCHEMBL26529925 | 0.86 | HDAC6 (0.53) | HDAC6HDAC1 | |
| SCHEMBL26530042 | 0.85 | HDAC6 (0.49) | HDAC6HDAC1 | |
| SCHEMBL26528722 | 0.84 | HDAC6 (0.59) | HDAC6HDAC1 | |
| SCHEMBL26529945 | 0.84 | HDAC6 (0.50) | HDAC6 | |
| SCHEMBL26529934 | 0.83 | HDAC6 (0.48) | HDAC6HDAC1 | |
| SCHEMBL26529939 | 0.83 | HDAC6 (0.50) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250230166-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4504190-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | Eikonizo Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC1 2/4885 |
| US-20250230166-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC1 2/4885 |
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC9 | HDAC6 1/4885HDAC1 2/4885 |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, CTTN | HDAC6 1/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.